Race specific comparisons of antihypertensive and metabolic effects of hydrochlorothiazide and chlorthalidone

For decades, thiazide diuretics (TZDs) have been the preferred initial therapy for uncomplicated hypertension1 –4. Though hydrochlorothiazide (HCTZ) is the most commonly prescribed TZD5,6, recent guidelines favor the long acting “thiazide-like” diuretics such as chlorthalidone (CTD) over “thiazide-type” diuretics (HCTZ) for better cardiovascular risk reduction4,7. There are no head to head outcomes trials of these agents, and data comparing blood pressure lowering and adverse events are inconsistent 8–11, with comparisons across non-equipotent or pooled doses8, and limited data at the clinically recommended low-doses12.

Source: The American Journal of Medicine - January 9, 2021 Category: General Medicine Authors: Lakshmi Manasa S. Chekka, Arlene B. Chapman, John G. Gums, Rhonda M. Cooper-DeHoff, Dean and Distinguished professor, Dr. Julie A. Johnson Tags: Clinical Research Study Source Type: research